独家专访 | 二十年磨一剑！他打破PHA成本困局，携万吨级技术回国圆梦！

Core Viewpoint - The article discusses the innovative approach of Yike Biotech in reducing the cost of PHA (polyhydroxyalkanoates) production to compete with petroleum-based materials, emphasizing the use of non-food plant oils as raw materials [3][4][9]. Group 1: Industry Background - The biodegradable materials market, including PLA and PBAT, has faced challenges such as overcapacity and performance limitations, leading to a decline in production rates [6][7]. - PHA is highlighted for its advantages, including marine biodegradability, heat resistance up to 100°C, and excellent barrier properties, with the global market expected to reach $367 million by 2030 [6][8]. Group 2: Company Overview - Yike Biotech was founded in June 2025 by Dr. Wilson Ling, who aims to revolutionize PHA production using non-food oils, specifically Pongamia oil, to significantly lower costs [9][10]. - The company has completed laboratory and pilot-scale validations of its production process and is the first globally to hold a PCT patent for PHA production [37]. Group 3: Cost Reduction Strategy - The raw material cost constitutes over 50% of PHA production costs, making it essential to lower these costs. Traditional sugar-based routes have a conversion rate of only 30%, leading to high costs [27][28]. - By using Pongamia oil, which has a conversion rate of over 80%, Yike Biotech can reduce PHA production costs by 30-50% compared to sugar-based methods [36]. Group 4: Technical and Market Development - Yike Biotech plans to focus on medical products for the Australian market, where demand is high, and the approval process is faster compared to other regions [38]. - The company aims to establish a production line in China that can replace 15,000 to 20,000 tons of petroleum-based plastics annually, with plans for further expansion [39].